Contribute Try STAT+ Today

Amid ongoing concern that Covid-19 therapies and vaccines may be unaffordable, a bipartisan group of lawmakers introduced a pair of bills that would prohibit drug makers from price gouging and also require all taxpayer-funded Covid-19 research to be recorded in a federal database.

The move comes as access to Covid-19 medical products emerges as a hot-button issue in the U.S. and elsewhere, with worries mounting over the extent to which a therapy or vaccine will be available in sufficient quantities at affordable prices. In February, Health and Human Services Secretary Alex Azar told Congress the Trump administration wanted to make products affordable, but could not control pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.